The first group consists of postmenopausal patients with HR-positive, HER2-negative, metastatic BC with PIK3CA mutation treated at least with a single line of endocrine-based therapy at the diagnosis of metastatic disease. This evidence concerns the gene PIK3CA and breast cancer.